Moderna (MRNA) Total Liabilities (2016 - 2026)

Moderna (MRNA) has 11 years of Total Liabilities data on file, last reported at $4.1 billion in Q1 2026.

• Total Liabilities for Q1 2026 came in at $4.1 billion, up 54.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.1 billion (up 54.66% YoY), and the FY2025 annual result was $3.7 billion, up 13.79% from the prior year.
• Total Liabilities improved to $4.1 billion in Q1 2026 per MRNA's latest filing, from $3.7 billion in the prior quarter.
• Over five years, Total Liabilities peaked at $10.5 billion in Q1 2022 and troughed at $2.6 billion in Q2 2025.
• A 5-year average of $5.0 billion and a median of $4.1 billion in 2026 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2023 and 2026: Total Liabilities slumped 50.05% in 2023, then jumped 54.66% in 2026.
• A 5-year view of Total Liabilities shows it stood at $6.7 billion in 2022, then tumbled by 32.12% to $4.6 billion in 2023, then declined by 29.11% to $3.2 billion in 2024, then climbed by 13.79% to $3.7 billion in 2025, then rose by 10.63% to $4.1 billion in 2026.
• Business Quant data shows MRNA's Total Liabilities at $4.1 billion in Q1 2026, $3.7 billion in Q4 2025, and $2.8 billion in Q3 2025.